Development Pipeline

Development Pipeline

Pivotal Trial
Development Trial

Poziotinib

  • Cohort 1: Previously treated patients with EGFR exon 20 insertion mutation positive NSCLC
    Preclinical Phase 1 Phase 2 Phase 3 Approved
  • Cohort 2: Previously treated patients with HER2 exon 20 insertion mutation positive NSCLC
    Preclinical Phase 1 Phase 2 Phase 3 Approved
  • Cohort 3: Treatment naïve patients with EGFR exon 20 insertion mutation positive NSCLC
    Preclinical Phase 1 Phase 2 Phase 3 Approved
  • Cohort 4: Treatment naïve patients with HER2 exon 20 insertion mutation positive NSCLC
    Preclinical Phase 1 Phase 2 Phase 3 Approved
For more information click here.

ROLONTIS® (eflapegrastim)

  • Chemotherapy-Induced Neutropenia (ADVANCE)
    Preclinical Phase 1 Phase 2 Phase 3 Approved
  • Chemotherapy-Induced Neutropenia (RECOVER)
    Preclinical Phase 1 Phase 2 Phase 3 Approved
For more information click here.

FIT Platform (Focused Interferon Therapeutics)

  • Interferon/CD20 Monoclonal Antibody Fusion Protein (Formerly IGN002)
    Preclinical Phase 1 Phase 2 Phase 3 Approved
  • Interferon/GRP94 Monoclonal Antibody Fusion Protein (Formerly IGN004)
    Preclinical Phase 1 Phase 2 Phase 3 Approved